Lantern Pharma (NASDAQ: LTRN) has announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), a real-time, web-based molecular intelligence engine. The enhanced platform allows researchers to generate comprehensive developability profiles for small molecules from a single SMILES input, leveraging Lantern’s RADR AI technology. This advancement provides rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture, and topological mapping, with benchmark-validated performance to streamline drug discovery workflows.
The expansion of predictBBB into an LQM marks a significant step in broadening access to advanced computational tools for drug development. By integrating the RADR AI platform, the new model delivers high-dimensional analysis that can evaluate multiple properties of candidate molecules simultaneously. Researchers can now obtain detailed profiles that include drug-likeness scores, structural characteristics, and topological maps, all from a single input. This capability is designed to accelerate the early stages of drug discovery by providing actionable insights quickly and efficiently.
Lantern Pharma is a clinical-stage precision oncology company that leverages AI and machine learning through its proprietary RADR platform. The company’s clinical pipeline includes LP-184, LP-284, and LP-300, with LP-184 also being developed for pediatric CNS cancers through Starlight Therapeutics, its wholly owned CNS-focused subsidiary. Additionally, Lantern has commercially launched withZeta.ai, a multi-agentic AI co-scientist platform available as a subscription-based research tool for the global biomedical community, representing a new revenue stream.
The predictBBB platform’s expansion into an LQM is expected to have implications for drug discovery efficiency, enabling researchers to rapidly assess the developability of small molecules. This could reduce the time and cost associated with early-stage drug development. The platform’s web-based accessibility also democratizes access to advanced computational tools, allowing a broader range of researchers to utilize these capabilities.
For more details, the full press release is available at https://ibn.fm/XqWld. More information about Lantern Pharma can be found at their newsroom https://ibn.fm/LTRN.
